Alnylam Pharmaceuticals, Inc.
TMPRSS6 iRNA compositions and methods of use thereof
Last updated:
Abstract:
The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as .beta.-thalassemia or hemochromatosis.
Status:
Grant
Type:
Utility
Filling date:
18 Aug 2020
Issue date:
27 Apr 2021